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Abstract Cardiovascular disease (CVD) is the leading cause of death in women, and knowledge of the clinical consequences of
atherosclerosis and CVD in women has grown tremendously over the past 20 years. Research efforts have increased
and many reports on various aspects of ischaemic heart disease (IHD) in women have been published highlighting sex
differences in pathophysiology, presentation, and treatment of IHD. Data, however, remain limited. A description of
the state of the science, with recognition of the shortcomings of current data, is necessary to guide future research
and move the field forward. In this report, we identify gaps in existing literature and make recommendations for
future research. Women largely share similar cardiovascular risk factors for IHD with men; however, women with
suspected or confirmed IHD have less coronary atherosclerosis than men, even though they are older and have
more cardiovascular risk factors than men. Coronary endothelial dysfunction and microvascular disease have been
proposed as important determinants in the aetiology and prognosis of IHD in women, but research is limited on
whether sex differences in these mechanisms truly exist. Differences in the epidemiology of IHD between women
and men remain largely unexplained, as we are still unable to explain why women are protected towards IHD
until older age compared with men. Eventually, a better understanding of these processes and mechanisms may
improve the prevention and the clinical management of IHD in women.
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1. Introduction
Cardiovascular disease (CVD) is the leading cause of death in both
women and men worldwide and a major cause of morbidity. Accord-
ing to the Global Burden of Disease, in 2004, CVD caused almost 32%
of deaths in women worldwide vs. 27% in men.1 In Europe, 54% of all
females’ death are from CVD vs. 43% in men.2 Ischaemic heart disease
(IHD), the most common form of CVD, is also the single most fre-
quent cause of death in Western countries. In Europe, over one in
five women (22%) and men (21%) die from IHD.2 With the ageing
of the population, and because of women’s longer life expectancy
than men, the proportion of persons, particularly women, who will
die of CVD is expected to rise even further in the upcoming decades.
2. Cardiovascular mortality
In many Western countries, cardiovascular mortality has declined
among women since the mid-1960s, as it has in men.3 In the USA,
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however, the total number of deaths due to CVD has slightly
increased in women up to the year 2000, whereas it has decreased
among men.4 This increase probably reflects changing population
demographics towards a larger proportion of older people, the
majority of whom are women. Indeed, when examining age-
standardized death rates rather than death counts, a similar decline
is noted in women and in men in the USA and many other
Western countries.3,5,6
After the year 2000, both the death rates and the number of car-
diovascular deaths have shown a similar, if not steeper, downward
trend in American women compared with men.4 However, when
looking at different age groups, the decrease in mortality appears to
have slowed down since 2000 in middle-aged women and men (age
35–54 years), whereas it has continued steadily among older
people.7 In addition to an overall decline in cardiovascular mortality
from population statistics, there has been a decline in hospital mor-
tality rates for acute myocardial infarction (AMI) among American
women and men of all ages, which has been more substantial in
women than in men.8
It should be noted that these favourable trends are not universal.
For example, they do not apply to Eastern Europe, where mortality
from both IHD and CVD is still rising for both women and men.
Exceptions are Hungary, whose rates levelled off (at very high
rates) in the mid-1990s, and Poland and the Czech Republic, whose
rates have tended to decline since the mid-1990s.3 In the Russian Fed-
eration, mortality rates from IHD and CVD for both women and men
during 1995–98 were among the highest in the world.
3. Risk factors
3.1 Traditional risk factors
As shown by the INTERHEART study, a large international case–
control study of AMI, risk estimates associated with traditional cardi-
ovascular risk factors are overall similar in women and men and across
various regions of the world.9 However, the increased risk associated
with hypertension and diabetes and the protective effect of exercise
and alcohol appear to be somewhat larger in women than in men.
Collectively, nine potentially modifiable risk factors (smoking, hyper-
tension, diabetes, waist/hip ratio, dietary patterns, physical activity,
consumption of alcohol, plasma apolipoproteins, and psychosocial
factors) account for 94% of the population attributable risk of AMI
in women and 90% in men.9 For young women with favourable
levels of all five major risk factors (smoking, hypertension, diabetes,
serum cholesterol and body mass index), IHD and CVD are rare
events.10 Unfortunately, only about 20% of women younger than 40
years of age meet these low-risk criteria10 and 48% of women have
a clustering of three or more metabolic risk factors for IHD.11
3.1.1 Smoking
Smoking is the single most important preventable cause of IHD in
women and the leading cause of IHD in women younger than 50
years old.12 There is a dose-dependent relationship between total
cigarettes consumption per day and risk of AMI; as few as one to
five cigarettes per day increase a patient’s risk.9,13 There is also a well-
established increased risk of venous thrombosis and IHD for women
who both smoke and use oral contraceptives.14 After cessation of
smoking, the risk of IHD in both women and men declines rapidly
(within months) and falls to the level of the risk among non-smokers
within 5–10 years.13,15 Exposure to passive smoking is also a risk
factor for IHD in women, increasing their risk of 24% (22% in
men).16 Although the prevalence of smoking is still slightly higher in
men than in women, the decline in tobacco use in recent decades
has been less pronounced in women than in men.
3.1.2 Hypertension
For women, as for men, hypertension is a major cause of IHD, as well
as of congestive heart failure and stroke.17 Hypertension is a highly
prevalent risk factor that becomes more common in women than
in men over the age of 55 years and is particularly prevalent among
black women.18 In the INTERHEART study, the population attribu-
table risk for hypertension was 36% in women, indicating that the
risk of AMI could be reduced by 36% where hypertension was elimi-
nated as a risk factor. The corresponding figure in men was 19%.9
Hypertension is two to three times more common in women
taking oral contraceptives, especially among obese and older
women, than in women not taking them.
In older women, isolated systolic hypertension is the most common
form of hypertension. A three-fold increase in IHD and stroke is
found in women with a systolic blood pressure .185 mmHg when
compared with women with a level of ,135 mmHg.19 Control of
any form of hypertension has been demonstrated to reduce the
risk of IHD and stroke in both sexes, as shown by large clinical
trials with a fair representation of women.20 Unfortunately,
the ongoing National Health and Nutrition Examination Study
(NHANES) survey has continued to show low rates of hypertension
awareness, treatment, and control among American women, as in
men, although these rates have increased over time.21,22
3.1.3 Dyslipidaemia
Almost half (48%) of American women 20 years of age or older have a
total cholesterol level ≥ 200 mg/dL, and almost one-third (32%) have
an LDL cholesterol ≥130 mg/dL.4 Although women aged 20–50
years tend to have more favourable lipid profiles than men, after
the onset of menopause cholesterol levels increase in women,
whereas they remain steady in men. Total and LDL cholesterol
levels predict fatal IHD in both middle-aged (,65 years) and older
(≥65 years) women, but the strength and consistency of these
relationships in older women is diminished.23
Reduced HDL cholesterol and high triglyceride levels appear to be
more important risk factors in women than in men. HDL cholesterol
inversely predicts IHD in both middle-aged and older women,
whereas it does not in older men.23 Among 32 826 post-menopausal
women from the Nurses’ Health Study, HDL cholesterol was the lipid
parameter that best discriminated the risk of IHD.24 Hypertriglyceri-
daemia, on the other hand, is associated with 37% increased CVD
risk in women, independent of other risk factors including HDL
cholesterol; the corresponding estimate for men is 14%.25
In women with known CVD, the treatment of hyperlipidaemia is
effective in reducing IHD events and IHD mortality, although it
does not affect total mortality. For women without CVD (primary
prevention), lipid lowering does not affect total or IHD mortality;
lipid lowering may reduce non-fatal IHD events, but evidence is insuf-
ficient to determine this conclusively.26 The recent Intervention Trial
Evaluating Rosuvastatin (JUPITER) evaluated the benefits of statin
therapy in apparently healthy individuals with elevated high-sensitivity
C-reactive protein but without an elevation in LDL cholesterol.
Among women, statin therapy significantly reduced the primary
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combined endpoint of AMI, stroke, hospitalization for unstable angina,
arterial revascularization, or cardiovascular death.27 However,
because of the small number of events, the absolute risk reduction
was small (about half of a percentage point) and the reduction of
‘hard’ endpoints such as fatal or non-fatal AMI, stroke or cardiovascu-
lar mortality or total mortality was not statistically significant. There-
fore, it is still debatable whether statins, or other lipid-lowering
medications, are useful for the primary prevention of CVD in
women. Given the small absolute risk of CVD in middle-aged
women (those mostly targeted by primary prevention efforts), con-
sideration of the risk/benefit ratio for any intervention is particularly
important.
3.1.4 Type 2 diabetes
Diabetes mellitus is a major risk factor for IHD for both men and
women, and among women, it nullifies the female protection
towards developing IHD compared with men.28 Although diabetes
has often been associated with a higher IHD risk in women than in
men, this is in part due to a higher rate of coexisting risk factors in
women with diabetes29 and to the better survival (relative to men)
of women without diabetes.28 The mortality rates of women with dia-
betes are actually similar, or less, that of men with diabetes.28,29 These
statistics, however, may be worsening. CVD mortality reductions in
the past 30 years have been achieved for diabetic men but not for dia-
betic women; a better survival for women with diabetes than men
noted in the 1970s and early 1980s was essentially eliminated in
1988–2000.30
3.1.5 Obesity
Obesity is an important risk factor for diabetes and CVD. It is found in
33% of women (and 31% of men), including 7% women (3% men)
being extremely obese, defined as a body mass index of ≥ 40.31
Obesity is particularly a problem among black women (54 vs. 30%
in white women); the prevalence of extreme obesity is 15% in this
group.31
There is a gradient of coronary risk with increasing overweight,
with the heaviest category of women having a four-fold increased
risk for CVD compared with lean women.32 Polycystic ovary syn-
drome is found in 10–13% of women but is often unrecognized; it
is linked with a clustering of risk factors, including obesity and type
2 diabetes mellitus, and increased IHD risk after menopause.33 There-
fore, polycystic ovary syndrome may contribute to the increased
cardiovascular risk associated with obesity among women.
3.1.6 Trends in risk factors
Over the 1990s, there have been mixed trends in CVD risk factors for
both women and men. On the positive side, between 1988 and 2002,
both sexes experienced a reduction in the prevalence of high-risk
levels of cholesterol; on the other hand, an increase in the prevalence
rates of obesity and elevated C-reactive protein was noted, particu-
larly among women.34 Furthermore, the proportion of women with
high blood pressure increased, whereas it decreased among men. A
recent update from the same ongoing US survey, up to 2004, pro-
vided additional evidence of a somewhat worsening risk factor
profile among women.35
3.2 Novel biomarkers
In an effort to improve risk prediction and guide prevention, more
than 100 new risk markers have been proposed particularly for the
large segment of the population who is currently classified as being
at intermediate risk based on existing risk algorithms. Consensus con-
ferences, however, have consistently recommended against the use of
these markers for lack of evidence that they help improve risk predic-
tion.36,37 A recent summary of systematic reviews conducted for the
United States Preventive Services Task Force has reviewed the evi-
dence concerning nine novel risk factors: C-reactive protein, coronary
artery calcium score as measured by electron-beam computed tom-
ography, lipoprotein(a) level, homocysteine level, leucocyte count,
fasting blood glucose, periodontal disease, ankle-brachial index, and
carotid intima–media thickness.38 Each factor’s potential clinical
value was evaluated by using a set of criteria that emphasized the
effect on the reclassification of intermediate-risk persons. This
review concluded that current evidence does not support the
routine use of any of the nine risk factors for screening and risk stra-
tification of intermediate-risk persons. Of the risk markers evaluated,
C-reactive protein was the best candidate for screening; however, evi-
dence is still lacking to recommend routine use. In women, in particu-
lar, a C-reactive protein level of .3.0 mg/L reclassified only 5% of
intermediate-risk women in the Women’s Health Study39 and none
in the Cardiovascular Health Study,40 suggesting a small and inconsist-
ent effect.38 However, when incorporated into the Reynolds Risk
Score, C-reactive protein assessment may be of utility in women, as
reported in more detail in the following section, although validation
of this risk algorithm is needed in different populations of women.
3.3 Risk scores for IHD
An increasing number of CVD risk factors have a cumulative effect on
IHD risk both in women and in men. For example, among women
aged 18–39 years without prior IHD enrolled in the Chicago Heart
Association Detection Project in Industry, the age-adjusted rate of
IHD per 10 000 person-years, after 31 years of follow-up, was
lowest for low-risk women (0.7) and increased with increasing
number of CVD risk factors to 2.4 in women with one risk factor
and to 5.4 in women with two or more risk factors.10 The INTER-
HEART study clearly demonstrated the cumulative effect of modifi-
able risk factors, including current or former smoking, diabetes,
hypertension, abdominal obesity, psychosocial stressors, irregular
consumption of fruits and vegetables, no alcohol intake, avoidance
of regular exercise, and plasma lipids.9
Probably, the best-known risk algorithm for IHD for asymptomatic
persons is the Framingham Risk Score (FRS), which includes age,
hypertension, smoking, diabetes, and hyperlipidaemia.41 A problem
with this score is that much of the middle-aged population is classified
as low to intermediate risk. This is particularly true for women: even
up to age 80 years, more than three quarters of women have a
10-year Framingham risk of ,10%.42 Many other risk scores have
been proposed that have mostly included the same traditional risk
factors, but have occasionally added other factors such as family
history, measures of social deprivation, or new biomarkers such as
C-reactive protein. Some of the scoring systems developed in
European countries include the SCORE (Systematic Coronary Risk
Evaluation), the ASSIGN (Assessing Cardiovascular Risk to Scottish
Intercollegiate Guidelines Network/SIGN to Assign Preventative
Treatment), and the QRISK (QRESEARCH cardiovascular risk
algorithm).43 Whether these risk scores perform better than the
FRS for risk prediction in women remains to be demonstrated.
A risk score that has been developed specifically for women is the
Reynolds Risk Score,44 whose main difference from the FRS is the
Ischaemic heart disease in women 11
incorporation of parental history of IHD and C-reactive protein. This
score reclassified 15% of intermediate-risk women to high risk in the
Women’s Health Study; therefore, it has promise. However, it needs
validation in other populations.
3.4 Psychosocial risk factors
There is growing evidence that psychological stress can influence the
onset and clinical course of IHD,45 and this may be especially true for
women. In the INTERHEART study, the combined exposure to psy-
chosocial risk factors including depression, perceived stress at home
or work, low locus of control, and major life events was significantly
associated with AMI with an adjusted odds ratio (OR) of 2.6 in men
and 3.5 in women.9 Individually, each of these factors predicted AMI
in a fairly similar fashion in both men and women.46
3.4.1 Depression
Depression is about two-fold more prevalent in women than in men;
it is especially common, up to 40%, in younger women with AMI.47
Depression is an important risk factor for adverse cardiac events in
women, increasing a woman’s risk of at least 50%.48–50 In addition
to cardiac outcomes, depression is related to worse quality of life
in cardiac patients51 and worse health status benefits after bypass
surgery, particularly in women.52 Furthermore, depression is one of
the strongest predictors of non-adherence to medical treatment53,54
and an important correlate of lifestyle behaviours such as smoking55
and sedentary lifestyle.56
3.4.2 Chronic emotional distress
Factors such as anxiety, marital stress, and exposure to early life
adversities have been linked to cardiovascular risk in women. On
the basis of a recent meta-analysis, anxiety is a moderate but indepen-
dent risk factor for incident IHD and cardiac death in both men and
women, although individual study results are heterogeneous.57 A
series of studies of Scandinavian women with acute coronary syn-
dromes have demonstrated robust associations of marital stress
with subsequent cardiac events,58 as well as with progression of cor-
onary artery disease measured with quantitative coronary angiogra-
phy.59 A study of US women also linked marital satisfaction to less
atherosclerosis in the carotid arteries and aorta measured by ultra-
sound and to less rapid progression of carotid atherosclerosis.60
Psychological trauma, particularly if occurring early in life, such as
childhood maltreatment, is an emerging risk factor for IHD which is
particularly common among women.61 Early trauma is also a risk
factor for depression,62 which may contribute to IHD risk in
women exposed to childhood trauma.
3.4.3 Acute stress
Acute psychological factors such as stressful events, acute anger,
sudden mood disturbances, and extreme excitement can trigger
AMI and sudden cardiac death in susceptible individuals.63 Although
it is unknown whether there are sex differences in these effects, a
stress-induced condition known as ‘takotsubo cardiomyopathy’ is
almost exclusively seen among women.64 It manifests as severe,
reversible left ventricular dysfunction, with markedly elevated levels
of plasma catecholamines.
3.4.4 Psychological interventions
Unfortunately, psychological interventions aimed at reducing stress or
treating depression or other psychosocial risk factors have shown
little to no effect on IHD incidence and total or cardiac mortality,
although they do achieve small reductions in anxiety and depression
in patients with IHD.65 When results are reported separately by
sex, men show a borderline statistically significant benefit [OR 0.73,
95% confidence interval (CI) 0.51–1.05], whereas in women, the esti-
mate is null (OR 1.01, 95% CI 0.46–2.23).66 It may be that traditional
psychosocial interventions do not work well for women and that
strategies that address more specifically women’s needs and stressors
should be developed. This is suggested by a recent study by Orth-
Gomer et al.,67 documenting a remarkable decrease in mortality
(about 70% lower) in women with IHD randomized to a stress-
reduction intervention specifically tailored to women, compared
with usual care. Although promising, the efficacy of such intervention
needs to be confirmed in other studies.
4. Pathophysiology
4.1 Atheroma burden and morphology
Women have less obstructive coronary artery disease than men along
the entire spectrum of acute coronary syndromes68–70 and across all
age groups.70 This advantage appears more marked in the coronary
tree than in other vascular beds. The population-based Rotterdam
Study examined sex differences in atherosclerosis at different sites
in the vascular tree among participants of age ≥55 years.71 A high
calcium score (.1000) was found more frequently in men than in
women in all age categories; interestingly, sex differences were
more evident in the coronary arteries than in other vascular terri-
tories. Nicholls et al.72 reported a lower atheroma volume in
women with angiographic coronary artery disease than in men, includ-
ing both intraluminal plaque and atheroma within the media, despite
the presence of more cardiovascular risk factors in women. Recently,
Han et al.,73 by measuring atheroma burden using intravascular ultra-
sonography, have extended this observation to patients without
obstructive coronary artery disease and demonstrated that even at
this early stage, women have a lower atheroma burden and different
atheroma morphology compared with men.
4.2 Vascular function
Community samples have demonstrated that women have better per-
ipheral endothelial function than men (measured as per cent of flow-
mediated vasodilation from baseline) until about age 70 and at all
levels of risk factors.74– 76 Better vascular function has also been
noted in women referred for coronary angiography but without
obstructive coronary artery disease, compared with men. In the
study by Han et al.,73 in addition to less plaque burden, women had
less diffuse epicardial endothelial dysfunction than men. Whether
better vascular function in women than men is also found among
patients with AMI or other acute coronary syndromes is not
known. However, abnormal endothelial function appears to be a
prognostic factor in women, as suggested by a small follow-up study
part of the Women’s Ischaemia Syndrome Evaluation (WISE)
study.77 More data are needed, however, to confirm these findings.
4.3 Vascular tissue repair
Ultimately, the balance between injury and repair is thought to be
the major determinant of CVD progression, with endothelial pro-
genitor cells (EPCs) playing an important role in vascular repair.
Endogenous mobilization of EPCs is associated with an enhanced
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re-endothelialization, an improvement of endothelial function, and a
reduced atherosclerotic burden. Thus, EPCs may provide a circulating
pool of cells that could constitute a cellular ‘repair’ mechanism at the
sites of vascular injury. A recent study based on 210 healthy subjects
(104 males and 106 females) demonstrated higher steady-state levels
of EPC (CD34+KDR+) in fertile women than in men, whereas they
were not different between post-menopausal women and age-
matched men.78 These sex gradients mirrored differences in cardio-
vascular profile, vascular function (brachial artery flow-mediated
dilation), and carotid intima–media thickness. EPCs are mobilized
cyclically in fertile women according to the menstrual cycle,78,79 in
synchrony with the level of circulating 17b-oestradiol,79 and they
could represent an important mechanism of protection for premeno-
pausal women. Therefore, oestrogen may play a role in stimulating
vascular repair; data from animal studies support this notion.80
4.4 Microvascular disease
Coronary microvascular dysfunction is a term used to designate
abnormalities in the vasomotor or metabolic regulation of the small
coronary arterioles (,500 mm in diameter), which are not visualized
by coronary angiography and are the main determinants of coronary
vascular resistance.81 It is a complex phenomenon that includes both
endothelium-dependent and -independent pathways but can also be
caused by structural changes in the vessel wall, such as vascular remo-
delling. Coronary microvascular disease may precede the develop-
ment of frank IHD and bears independent prognostic significance.82
Coronary microcirculatory function can be assessed invasively by
measuring coronary flow reserve in response to adenosine with an
intracoronary Doppler wire. Non-invasive methods for the measure-
ment of coronary flow reserve include positron emission tomography,
magnetic resonance imaging, and transthoracic echocardiography with
contrast material.81
According to experimental studies, sex plays a relevant role in a
number of microvascular mechanisms which may affect microvascular
function and disease. Sex-specific differences in microvascular blood
flow and vasodilatory capacity are observed very early in develop-
ment. In a study on skin microcirculation in newborn preterm
(24–28 weeks) infants, Stark et al.83 observed that male infants had
higher baseline flow than females. In animal experiments, differences
in superoxide concentration and vascular permeability of venules
were also described.84 Some of the reported sex differences are
related to gonadal hormones and their receptors. However, genetic
differences may also exert effects independent from gonadal
function.85
On the basis of experimental data and clinical observation, coron-
ary microvascular dysfunction is put forth as a major aetiological
factor for IHD in women and a frequent determinant of chest pain
in the absence of significant coronary obstruction—known as syn-
drome X or ‘microvascular angina’.86,87 To date, however, microvas-
cular angina remains a controversial entity,88 and few clinical studies
have addressed the role of microvascular dysfunction as a determinant
of IHD in women other than within the context of cardiac syndrome
X. In a recent follow-up study of 189 WISE women with suspected
coronary ischaemia, coronary flow reserve after intracoronary adeno-
sine was significantly related to increased risk of major adverse out-
comes (death or hospitalization for non-fatal AMI, congestive heart
failure or stroke), with an adjusted hazards ratio of 1.14 per unit
decrease in log-transformed coronary flow reserve.89 Data are
needed in less selected samples of women, and using non-invasive
methods of coronary flow reserve, to confirm these findings. Also,
data are needed to support the concept that this phenomenon is
more prevalent among women than men. Currently, the only proof
is the observation that cardiac syndrome X is more frequent in
women than in men, but this syndrome only accounts for a small pro-
portion of IHD in women. The few studies that have compared cor-
onary flow reserve in response to adenosine between women and
men referred for coronary angiography have found similar
values.73,90 In one study, coronary flow reserve was lower in
women, but the difference was largely explained by women’s older
age and smaller body size.73
4.5 Autonomic function
There are important sex differences in the autonomic nervous control
of the cardiovascular system. Men tend to have a higher sympathetic
cardiac autonomic activity, whereas women tend to have a higher
parasympathetic activity.91 These differences may be the result of
developmental differences (e.g. body fat distribution) or hormonal
differences between women and men.91,92 Other factors that modu-
late or alter autonomic cardiac activity, and may potentially influence
sex differences, include age,93 obesity,92 changes in hormone levels,91
inflammation,94 and psychological disorders (e.g. depression).95
Airaksinen et al.96 showed that vagal activation was more common
in women than men during acute coronary occlusion, suggesting that
this might have beneficial antiarrhythmic effects. However, in patients
with cardiac syndrome X, who are mostly post-menopausal women,
an imbalance of autonomic nervous activity has been reported.
Lanza et al.97 showed I-metaiodobenzylguanidine myocardial scintigra-
phy defects, a measure of autonomic nervous system activity, in 75%
of cardiac syndrome X patients (64% women). In addition, in patients
with cardiac syndrome X, a relationship between vagal impairment,
measured by means of heart rate variability, and non-invasive coron-
ary flow reserve measurements has been described.98 Furthermore,
Ponikowski et al.99 showed that marked vagal withdrawal, detected
by heart rate variability analysis, preceded ST-segment depression
on 24 h Holter monitoring in a predominantly female sample (19
women out of 23 patients). Although it is known that women are
more often affected by cardiac syndrome X than men, no study so
far has been conducted to examine sex differences in cardiac auto-
nomic activity in a broad range of IHD patients.
Another condition in which autonomic dysfunction is likely to play a
pathogenic role is takotsubo cardiomyopathy. A recent study showed
significant impairment in heart rate variability at the index event com-
pared with after 3 months,100 suggesting that acute autonomic dys-
function may induce neurogenic stunning of the myocardium leading
to the clinical picture of stress-induced cardiomyopathy. Therefore,
although women have normally a more favourable autonomic func-
tion profile than men, specific syndromes that are more common
among women (cardiac syndrome X and takotsubo cardiomyopathy)
are paradoxically linked to adverse autonomic function.
4.6 Role of sex hormones
The lower incidence of CVD in premenopausal women compared
with men of similar age and the menopause-associated increase in
CVD have long suggested that ovarian hormones underlie a protec-
tive effect on the cardiovascular system for women. Indeed, sex
steroid hormones exert multiple direct and indirect effects on cardi-
ovascular physiology.101 Up to now, research has focused on the
effects of oestrogen and oestrogen receptors (ERs), whereas other
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hormones, such as progesterone and testosterone and their recep-
tors (PR and AR), have received much less consideration.
4.6.1 Cardiovascular effects of oestrogens
Oestrogens improve the arterial wall response to injury and
inhibit the development of atherosclerosis by promoting
re-endothelialization, inhibiting smooth muscle cell proliferation, and
matrix deposition following vascular injury.102 Oestrogens also
decrease systemic vascular resistance, improve coronary and periph-
eral endothelial function, and prevent coronary artery spasm in
women with and without coronary atherosclerosis.103,104 Interest-
ingly, intracoronary infusion of oestradiol improves endothelial func-
tion and coronary blood flow in female patients, but not in male
patients with coronary artery disease.104
Oestrogens cause vasodilation through both rapid increases in the
production of nitric oxide (NO) and the induction of NO genes.102
Oestrogens also modulate relaxation through the endothelium-
derived hyperpolarizing factor,105 by inducing vasodilator prostanoids
(PGE2 and PGI2)
106 and by inhibiting the production of
endothelin-1.107 Additionally, oestrogens modulate myogenic vascular
responses by reducing the basal tone of microvessels.106 The majority
of these effects have been attributed to oestrogens acting on two dis-
tinct receptors, ERa and ERb, which are expressed both in vascular
endothelial and smooth muscle cells.102 ERa appears to mediate
most of the protective effects of oestrogen against vascular injury
and atherosclerosis.108 ERb expression is enhanced in the vascular
wall of women with IHD, whereas ERa predominates in unaffected
women.109
Most of the data on the cardiovascular effects of oestrogens relate
to vascular function. Much less is known about oestrogens effects on
the myocardium. ERb is present in myocardial cells, where it regulates
the expression of NO synthases.110 Additionally, oestrogens affect sig-
nalling of genes involved in cardiac conduction, such as Isk and HK2
(cardiac potassium channels) and connexion 43.110 In female mice,
for example, oestrogens have been shown to prolong AV nodal con-
duction and the right ventricular effective refractory period.111
In addition to oestrogens, progesterone may also contribute to sex-
specific differences in the regulation of vascular function; its effects,
however, remain controversial.112 Testosterone, on the other hand,
was shown to have adverse effects on blood pressure and cardiovas-
cular morbidity and mortality.113
4.6.2 Post-menopausal hormone therapy
Given the many potentially beneficial effects of oestrogens on cardi-
ovascular physiology, much expectation was placed on the protective
effects of post-menopausal hormone therapy for CVD prevention in
women. Initial observational studies did show a reduced incidence of
CVD in post-menopausal women using hormone therapy compared
with non-users.114,115 However, it has recently become clear that
hormone therapy has complex biological effects, e.g. it has both anti-
inflammatory and proinflammatory effects and it both activates coagu-
lation and improves fibrinolysis.116 Effects depend on many factors,
including route of administration, doses of oestrogens, and age of
the women, among others. Given orally, hormone therapy clearly
increases C-reactive protein.117
The Heart and Estrogen/Progestin Replacement Study (HERS), and
the Women’s Health Initiative (WHI) clinical trials did not support
beneficial effects of hormone therapy in post-menopausal women,
neither in secondary nor in primary cardiovascular prevention.118–120
In fact, the WHI study was terminated early due to a small but signifi-
cant increase in cardiovascular events and other adverse outcomes in
the hormone therapy group. In trying to explain these unexpected
results, it has been argued that the timing of initiation of hormone
therapy after the onset of menopause may influence the response
to treatment for CVD prevention. Post hoc analyses of the WHI
trial suggested that the CVD risk may be decreased when oestrogen-
only therapy is started earlier, within 10 years of menopause, but
results were not statistically significant.121 For the combination of oes-
trogen and progestin therapy, there was no indication of a decreased
CVD even among women who initiated therapy within 10 years after
menopause; a possible cardioprotective effect in these women
became apparent only after 6 years of use.122 Because the typical dur-
ation of hormone therapy is ,10 years, most women considering
combined oestrogen plus progestin therapy for the relief of menopau-
sal symptoms should not expect protection against CVD. Thus, no
trial of hormone therapy has conclusively demonstrated a beneficial
effect towards CVD in either primary or secondary prevention; if any-
thing, risk is slightly increased. Therefore, hormone therapy should
not be used for the prevention of CVD in women.
5. Conclusions and
recommendations for future
research
Women largely share similar cardiovascular risk factors for IHD with
men; however, there are important sex differences in the prevalence
of coronary atherosclerosis and coronary vascular physiology with
relevance to IHD risk. Experimental data suggest complex differences
in the regulation of vasomotor function of microvessels of females and
males. These experimental findings contribute to the understanding of
sex differences in IHD. A larger role has been proposed for coronary
endothelial dysfunction and microvascular disease in the aetiology and
prognosis of IHD in women than in men, but research is limited. Key
questions remain about the prevalence of these vascular abnormalities
in women with and without symptomatic IHD and whether they affect
women more than men. More data are also needed to explain why
women are protected towards IHD until older age. Differences in
epidemiology may reflect important aspects of cardiovascular patho-
physiology that differ between the sexes. Eventually, a better under-
standing of these processes may improve the clinical management
of IHD in women, because it may help to devise new strategies for
the prevention, detection, and treatment of IHD that are better tai-
lored to women.
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